The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking effective therapy. Many TNBCs show remarkable response to carboplatin-based chemotherapy, but often develop resistance over time. With increasing use of carboplatin in the clinic, there is a pressing...
Enregistré dans:
Auteurs principaux: | Stijn Moens, Peihua Zhao, Maria Francesca Baietti, Oliviero Marinelli, Delphi Van Haver, Francis Impens, Giuseppe Floris, Elisabetta Marangoni, Patrick Neven, Daniela Annibali, Anna A. Sablina, Frédéric Amant |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/23a5f34fef334ff789f85c69f707a9be |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A Dynamical Model for Activating and Silencing the Mitotic Checkpoint
par: Richard Henze, et autres
Publié: (2017) -
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
par: Miguel Martin, et autres
Publié: (2021) -
Inner centromere localization of the CPC maintains centromere cohesion and allows mitotic checkpoint silencing
par: Rutger C. C. Hengeveld, et autres
Publié: (2017) -
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
par: Abdel Kader Y, et autres
Publié: (2013) -
The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells
par: Yainyrette Rivera-Rivera, et autres
Publié: (2021)